ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-259-1970
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees48
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) issued its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
5 brokers have issued 12 month price targets for ZIOPHARM Oncology's shares. Their forecasts range from $5.00 to $7.50. On average, they expect ZIOPHARM Oncology's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.
What is the consensus analysts' recommendation for ZIOPHARM Oncology?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZIOPHARM Oncology.
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/18/2019)
- 2. HC Wainwright analysts commented, "We have updated our model to reflect the reported 1Q19 financial results, and we project revenues of $3.2M and a net loss of $0.33 per share for 2019. The company reported cash and cash equivalents of $51.5M at the end of 1Q19, which we believe is sufficient to maintain operations until 2Q20. Clinical updates on controlled IL-12 at ASCO. Management announced that two clinical updates on its controlled IL-12 program (Ad-RTS-hIL-12 plus veledimex) for the treatment of recurrent GBM (rGBM) are expected to be presented at the 2019 Oncology (ASCO) Annual Meeting in June. Recall, Ziopharm is conducting two Phase 1 studies to evaluate the IL-12 platform as a monotherapy or as combination therapy with nivolumab (marketed by Bristol-Myers Squibb (BMY; not rated) as Opdivo)." (5/9/2019)
Has ZIOPHARM Oncology been receiving favorable news coverage?
Headlines about ZIOP stock have trended negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ZIOPHARM Oncology earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX), Mirati Therapeutics (MRTX), The Medicines (MDCO), PTC Therapeutics (PTCT), Uniqure (QURE), Myokardia (MYOK), Ligand Pharmaceuticals (LGND), Insmed (INSM), Emergent Biosolutions (EBS) and Portola Pharmaceuticals (PTLA).
What other stocks do shareholders of ZIOPHARM Oncology own?
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper, CEO & Director (Age 54)
- Dr. David M. Mauney M.D., Pres (Age 50)
- Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 63)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
- Mr. David Connolly, VP of Corp. Communications & Investor Relations
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.83%), Geode Capital Management LLC (1.08%), Northern Trust Corp (1.03%), Morgan Stanley (0.75%), Charles Schwab Investment Management Inc. (0.51%) and California State Teachers Retirement System (0.12%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which major investors are selling ZIOPHARM Oncology stock?
ZIOP stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Ibex Investors LLC, Morgan Stanley, Private Advisor Group LLC, Virtu Financial LLC, The Manufacturers Life Insurance Company , Commonwealth Equity Services LLC and California State Teachers Retirement System. View Insider Buying and Selling for ZIOPHARM Oncology.
Which major investors are buying ZIOPHARM Oncology stock?
ZIOP stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, BlackRock Inc., Iridian Asset Management LLC CT, Charles Schwab Investment Management Inc., HighTower Advisors LLC, State of Wisconsin Investment Board, BNP Paribas Arbitrage SA and BlueCrest Capital Management Ltd. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $4.39.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $712.45 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-53,120,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. ZIOPHARM Oncology employs 48 workers across the globe.
What is ZIOPHARM Oncology's official website?
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
